Global Unfractionated Heparin Market Growth 2025-2031
Description
The global Unfractionated Heparin market size is predicted to grow from US$ 1059 million in 2025 to US$ 1320 million in 2031; it is expected to grow at a CAGR of 3.7% from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Unfractionated Heparin (UFH) is a fast-acting anticoagulant (blood thinner) used to prevent and treat blood clots. It is derived from animal tissues (usually pig intestines or cow lungs) and consists of a mixture of glycosaminoglycan chains of varying lengths.
Although heparin can be synthesized by means of chemical processes, most of the worldwide produced heparin is extracted from animal tissue, porcine intestinal mucosa specifically. The production of heparin is located near the source of raw material. Area’s like China, North America and Europa are the main pork producing areas and these are also the locations of the main heparin producers. More than 65% of the world's heparin APIs are supplied by Chinese companies.
Heparin’s main source, porcine intestinal mucosa, is a by-product of pork slaughtering and is released while cleaning the pork’s casing. Cleaning casings is a specialized process that requires highly skilled staff and state of the art equipment. To avoid degradation of the heparin content and decay, stabilizing agent is added directly after harvesting. The material is stored in bulk tanks awaiting transport to the processing facility. There are also some Bovine-derived APIs on the market, but they are very few, accounting for about 2% to 4% of the global market share.
The North American and European markets lead in demand due to a high prevalence of thrombosis-related conditions and advanced healthcare infrastructure. Asia-Pacific is emerging as a growth market, driven by increased healthcare spending and the rise of generics.
LP Information, Inc. (LPI) ' newest research report, the “Unfractionated Heparin Industry Forecast” looks at past sales and reviews total world Unfractionated Heparin sales in 2024, providing a comprehensive analysis by region and market sector of projected Unfractionated Heparin sales for 2025 through 2031. With Unfractionated Heparin sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Unfractionated Heparin industry.
This Insight Report provides a comprehensive analysis of the global Unfractionated Heparin landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Unfractionated Heparin portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Unfractionated Heparin market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Unfractionated Heparin and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Unfractionated Heparin.
This report presents a comprehensive overview, market shares, and growth opportunities of Unfractionated Heparin market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Heparin Sodium
Heparin Calcium
Segmentation by Application:
Deep Vein Thrombosis (DVT)
Pulmonary Embolism (PE)
Myocardial Infarction
Unstable Angina
Atrial Fibrillation-related Clots
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Sanofi
Pfizer
Organon Canada
Leo Pharma
Panpharma
Rotexmedica GmbH
Bharat Serums and Vaccines
Troikaa Pharmaceuticals
Wellona Pharma
B. Braun
Bioiberica
Sagent Pharmaceuticals, Inc
Gland Pharma Limited
Stanex
Mylan
Rewine Pharmaceutical
Jianyou Pharmaceutical
Shenzhen Techdow Pharmaceutical
Changshan Pharma
Dongcheng Pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Unfractionated Heparin market?
What factors are driving Unfractionated Heparin market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Unfractionated Heparin market opportunities vary by end market size?
How does Unfractionated Heparin break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Unfractionated Heparin (UFH) is a fast-acting anticoagulant (blood thinner) used to prevent and treat blood clots. It is derived from animal tissues (usually pig intestines or cow lungs) and consists of a mixture of glycosaminoglycan chains of varying lengths.
Although heparin can be synthesized by means of chemical processes, most of the worldwide produced heparin is extracted from animal tissue, porcine intestinal mucosa specifically. The production of heparin is located near the source of raw material. Area’s like China, North America and Europa are the main pork producing areas and these are also the locations of the main heparin producers. More than 65% of the world's heparin APIs are supplied by Chinese companies.
Heparin’s main source, porcine intestinal mucosa, is a by-product of pork slaughtering and is released while cleaning the pork’s casing. Cleaning casings is a specialized process that requires highly skilled staff and state of the art equipment. To avoid degradation of the heparin content and decay, stabilizing agent is added directly after harvesting. The material is stored in bulk tanks awaiting transport to the processing facility. There are also some Bovine-derived APIs on the market, but they are very few, accounting for about 2% to 4% of the global market share.
The North American and European markets lead in demand due to a high prevalence of thrombosis-related conditions and advanced healthcare infrastructure. Asia-Pacific is emerging as a growth market, driven by increased healthcare spending and the rise of generics.
LP Information, Inc. (LPI) ' newest research report, the “Unfractionated Heparin Industry Forecast” looks at past sales and reviews total world Unfractionated Heparin sales in 2024, providing a comprehensive analysis by region and market sector of projected Unfractionated Heparin sales for 2025 through 2031. With Unfractionated Heparin sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Unfractionated Heparin industry.
This Insight Report provides a comprehensive analysis of the global Unfractionated Heparin landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Unfractionated Heparin portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Unfractionated Heparin market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Unfractionated Heparin and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Unfractionated Heparin.
This report presents a comprehensive overview, market shares, and growth opportunities of Unfractionated Heparin market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Heparin Sodium
Heparin Calcium
Segmentation by Application:
Deep Vein Thrombosis (DVT)
Pulmonary Embolism (PE)
Myocardial Infarction
Unstable Angina
Atrial Fibrillation-related Clots
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Sanofi
Pfizer
Organon Canada
Leo Pharma
Panpharma
Rotexmedica GmbH
Bharat Serums and Vaccines
Troikaa Pharmaceuticals
Wellona Pharma
B. Braun
Bioiberica
Sagent Pharmaceuticals, Inc
Gland Pharma Limited
Stanex
Mylan
Rewine Pharmaceutical
Jianyou Pharmaceutical
Shenzhen Techdow Pharmaceutical
Changshan Pharma
Dongcheng Pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Unfractionated Heparin market?
What factors are driving Unfractionated Heparin market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Unfractionated Heparin market opportunities vary by end market size?
How does Unfractionated Heparin break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
138 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Unfractionated Heparin by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Unfractionated Heparin by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
